Microcap biopharmaceutical researcher Adventrx Pharmaceuticals (ANX +11.2%) gets a pop today...


Microcap biopharmaceutical researcher Adventrx Pharmaceuticals (ANX +11.2%) gets a pop today after announcing that it's initiated patient recruitment for its Phase 3 clinical study of ANX-188 in sickle cell disease. Santosh Vetticaden, the company's Chief Medical Officer, says the drug "has the potential to be the first FDA-approved product for sickle cell disease vaso-occlusive crisis in fifteen years."

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs